Two cases of pancytopenia induced by ticlopidine.
- Author:
Chi Young PARK
1
;
Ji Eun KANG
;
Hyun Seong YIM
;
Choon Hae CHUNG
Author Information
1. Department of Internal Medicine, College of Medicine, Chosun University, Gwangju, Korea. chchung@mail.chosun.ac.kr
- Publication Type:Case Report
- Keywords:
Ticlopidine;
Aplastic Anemia
- MeSH:
Anemia, Aplastic;
Cerebral Infarction;
Granulocyte Colony-Stimulating Factor;
Humans;
Neutropenia;
Pancytopenia*;
Platelet Aggregation;
Thrombocytopenia;
Ticlopidine*
- From:Korean Journal of Medicine
2003;65(Suppl 3):S841-S843
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Ticlopidine is an inhibitor of platelet aggregation used in the management and prevention of thromboembolic disorders. Hematological toxicity is one of the most important side effects of ticlopidine, including neutropenia, thrombocytopenia and more seriously aplastic anemia. We reported here two cases of very severe aplastic anemia developed after the use of ticlopidine. Both patients suffered from an acute cerebral infarction. Both patients developed pancytopenia 56 days and 51 days after treatment with 500 mg of ticlopidine daily. Both patients were hospitalized and received empiric antibiotic therapy and G-CSF. Twenty-three days and thirty days after the withdrawal of ticlopidine, the hematologic parameters of each patient improved.
